Brief: Entera Bio Announces FDA Agreement For A Single Phase 3 Clinical Trial To Support An NDA For EB613
06/10/2022 12:06
Oct 6 (Reuters) - Entera Bio Ltd 5DT.F :
* ENTERA BIO ANNOUNCES FDA AGREEMENT FOR A SINGLE PHASE 3
CLINICAL
TRIAL TO SUPPORT AN NDA FOR EB613 FOR THE TREATMENT OF
OSTEOPOROSIS
* ENTERA BIO LTD - FDA AGREED TOTAL HIP BMD COULD SERVE AS
PRIMARY
ENDPOINT FOR REGISTRATIONAL STUDY OF EB613 IN POST-MENOPAUSAL
OSTEOPOROSIS PATIENTS
* ENTERA BIO LTD - LOOK FORWARD TO ADVANCING EB613 INTO
PHASE 3
AND INITIATING PATIENT ENROLLMENT DURING 2023
Source text for Eikon: ID:nGNX2gqnY0
Further company coverage: 5DT.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement